Tetra Bio-Pharma Signs a Definitive Distribution Agreement with DanCann Pharma to Monetize Its Dronabinol and Botanical Product Portfolios

May 5, 2021 3:00 AM

This Definitive Agreement is expected to generate an excess of $47,5M CAD in revenue for Tetra OTTAWA, ON / ACCESSWIRE / May 5, 2021 / Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX:TBP)(OTCQB:TBPMF)(FSE:JAM1), a leader in cannabinoid-derived drug discovery and development announced today the signing of a Definitive Agreement with DanCann Pharma A/S (SS: DANCAN) for the exclusive distribution of Reduvo™...

Read more

Apollo Endosurgery, Inc. Reports 29% Increase in First Quarter Revenue

May 4, 2021 4:01 PM

Conference Call to Discuss Results Today at 3:30 p.m. CT / 4:30 p.m. ET AUSTIN, TX / ACCESSWIRE / May 4, 2021 / Apollo Endosurgery, Inc. ("Apollo") (NASDAQ:APEN), a global leader in less invasive medical devices for gastrointestinal and bariatric procedures, today announced financial results for the first quarter ended March 31, 2021. Highlights Total revenue of $13.9 million, an increase of 29% from the first quarter of...

Read more

Havn Labs Jamaica Facility Now Fully Operational

May 4, 2021 8:00 AM

The Company has started production of its first grow with local partner Hypha Wellness VANCOUVER, BC / ACCESSWIRE / May 4, 2021 / Havn Life Sciences Inc. (CSE:HAVN)(OTC PINK:HAVLF)(FSE:5NP) (the "Company" or "Havn Life"), a biotechnology company pursuing standardized extraction of psychoactive compounds and the development of natural healthcare products, is pleased to announce that it now has a fully operational mycology...

Read more

Nascent Biotech Continues Anti-Dilution Campaign with Preemptive Settlement of Outstanding Convertible Note

May 4, 2021 8:00 AM

SAN DIEGO, CA / ACCESSWIRE / May 4, 2021 / Nascent Biotech, Inc. (OTCQB:NBIO) ("Nascent Biotech", "Nascent", or the "Company"), a clinical-stage biotechnology company pioneering the development of monoclonal antibodies targeting treatment of various cancers and viral infections, is pleased to announce further strides toward the elimination of toxic debt and dilution risk with the preemptive settlement of its...

Read more

Tetra Bio-Pharma Re-activates Veterinary Clinical Study in Companion Animals

May 4, 2021 7:30 AM

A first of its kind synthetic cannabinoid medication to manage eye pain in the veterinary setting OTTAWA, ON / ACCESSWIRE / May 4, 2021 / Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX:TBP) (OTCQB:TBPMF) (FRA:JAM1), a biopharmaceutical pioneer in immunomodulator drug discovery and development is pleased to announce that it has received authorization from the Veterinary Drugs Directorate of Health Canada for a one...

Read more

Interim Management Statement Q1 2021: Major Advances in COVID-19 Program, Continued Progress in Oncology Pipeline

May 4, 2021 1:00 AM

ZURICH-SCHLIEREN, SWITZERLAND / ACCESSWIRE / May 4, 2021 / Molecular Partners AG (SIX:MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin® therapeutics, announced today its interim management statement for the period ending March 31, 2021. "Molecular Partners continues to grow and expand the reach of our DARPin® therapeutics platform, with the COVID-19 pandemic...

Read more

Viewpoint Molecular Targeting(TM) Appoints Frank Morich, M.D., Ph.D. to its Board of Directors

May 3, 2021 10:00 AM

- Dr. Morich is an industry leader with over 35 years of experience in biopharmaceuticals with focus in commercialization, R&D and product development - - Previously served as Chief Commercial Officer of Takeda Pharmaceutical Company, Chief Executive Officer of Takeda Pharmaceutical International, Chief Executive Officer of NOXXON Pharma AG, Chief Executive Officer of Innogenetics N.V., and Head of Global Product Development of Bayer AG...

Read more

CO2 GRO Inc. Grants Stock Options

May 3, 2021 8:30 AM

TORONTO, ON / ACCESSWIRE / May 3, 2021 / CO2 GRO Inc. ("GROW" or the "Company") (TSXV: GROW, OTCQB: BLONF, Frankfurt: 4021) announces that the Board of Directors has approved the grant of 1,680,000 stock options (the "Options") to participants of the Company's stock option plan (the "Plan"). The Options are exercisable into common shares of the Company at an exercise price of $0.32 per share over the...

Read more

Noetic Foundry Appoints Dr. Tim Piser as Chief Scientific Officer

May 3, 2021 8:00 AM

TORONTO, ON / ACCESSWIRE / May 3, 2021 / Noetic Foundry, an operating company building psychedelic biotechnology startups, is pleased to announce the appointment of Dr. Tim Piser as its Chief Scientific Officer. Dr. Piser has over 25 years of neuroscience drug discovery and development expertise at both large pharmaceutical and early-stage biotechnology companies. His career has been driven by the overarching desire to develop novel medicines...

Read more

MJ Biotech, Inc. Submits Final Designs for CBD Extraction Facility, and a Second Foundation for Further Expansion

May 3, 2021 7:35 AM

CHEYENNE, WY / ACCESSWIRE / May 3, 2021 / MJ Biotech, Inc. (OTC PINK:MJTV) partner, Genesis Botanical Research (GBR), is pleased to report they have broken ground on a second foundation which will be used to store hemp biomass. Plans for the structure arrived at GBR corporate offices, and several contractors are currently placing bids for the erection of the structure. Upon completion of this process, plans will be submitted for official town...

Read more

Apollo Endosurgery Announces Appointments to Commercial Leadership Team

May 3, 2021 7:00 AM

Kirk Ellis to Serve as Vice President of US Sales Steve Bosrock to Serve as Vice President of Marketing & Medical Education AUSTIN, TX / ACCESSWIRE / May 3, 2021 / Apollo Endosurgery, Inc. ("Apollo") (NASDAQ:APEN), a global leader in minimally invasive medical devices for gastrointestinal and bariatric procedures, today announced the appointments of Kirk Ellis as Vice President of US Sales and Steve Bosrock as Vice President...

Read more

Tetra Bio-Pharma Granted a Drug Establishment License to Distribute REDUVO Soft Gel Capsules in Canada

May 3, 2021 6:30 AM

The addressable market in Canada is estimated to be $80M CDN by 2022. Tetra also applies for a Health Canada Cannabis Drug License OTTAWA, ON / ACCESSWIRE / May 3, 2021 / Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX:TBP)(OTCQB:TBPMF)(FRA:JAM1), a leader in cannabinoid-derived drug discovery and development today announced that the Company has been granted a Health Canada Drug Establishment License (DEL) to...

Read more

RepliCel Announces Appointment of Leading Sports Medicine Expert as Orthopedics Clinical Advisor (Japan)

May 3, 2021 6:00 AM

Professor Tsukasa Kumai, member of the Japan's Olympic Committee Medical and Scientific Staff, will lead RepliCel's Tendon Regeneration Clinical Testing in Japan VANCOUVER, BC / ACCESSWIRE / May 3, 2021 / RepliCel Life Sciences Inc. (OTC PINK:REPCF)(TSXV:RP)(FRA:P6P2) ("RepliCel" or the "Company"), a company developing next-generation technologies in aesthetics and orthopedics, is pleased to announce that...

Read more

Binovi Completes Motion Tracking Software Acquisition

April 30, 2021 4:00 PM

VANCOUVER, BC / ACCESSWIRE / April 30, 2021 / Binovi Technologies Corp. ("Binovi" or the "Company') (TSXV:VISN)(OTCQB:BNVIF)(GR:2EYA) a leader in neuro-vision performance technology, is pleased to announce that further to its news release dated April 16, 2021, the Company has completed the acquisition of all the issued and outstanding share capital of Samurai Motion Tracking Software (the "Acquisition") and thereby...

Read more

Dyadic to Report First Quarter 2021 Financial Results

April 29, 2021 4:00 PM

JUPITER, FL / ACCESSWIRE / April 29, 2021 / Dyadic International, Inc. ("Dyadic", "we", "us", "our", or the "Company") (NASDAQ:DYAI), a global biotechnology company focused on further improving, applying and deploying its proprietary C1-cell protein production platform to accelerate development, lower production costs and improve the performance of biologic vaccines and drugs at flexible commercial scales, today announced that it will report its...

Read more

Calyxt Successfully Transforms Hemp Genome

April 29, 2021 8:31 AM

New Hemp Transformation Technology Unlocks Capabilities to Selectively Breed and Deliver Improvements in Hemp Traits for Key Markets Including Protein, Fiber, Advanced Materials and Wellness Patent-Pending Transformation Process is Calyxt's First Announced Innovation in a Broad Hemp Improvement Pipeline ROSEVILLE, MN / ACCESSWIRE / April 29, 2021 / Calyxt, Inc. (NASDAQ:CLXT), a plant-based technology company, announced today that it has...

Read more

RepliCel Closes Second Tranche of Strategic Investment Commitment

April 29, 2021 6:00 AM

MainPointe Pharmaceuticals Completes Largest Scheduled Share Purchases per Investment Agreement VANCOUVER, BC / ACCESSWIRE / April 29, 2021 / RepliCel Life Sciences Inc. (OTC PINK:REPCF) (TSXV:RP) (FRA:P6P2) ("RepliCel" or the "Company"), a company developing next-generation technologies in aesthetics and orthopedics, announced today it has closed the second tranche of the investment by MainPointe Pharmaceuticals...

Read more

Experion Holdings Reports Record Revenue and First Quarter of Positive Adjusted EBITDA

April 28, 2021 4:30 PM

VANCOUVER, BC / ACCESSWIRE / April 28, 2021 / Experion Holdings Ltd. (the "Company" or "Experion") (TSXV:EXP)(OTCQB:EXPFF)(FRANKFURT:MB31), Canada's solution to craft cannabis supply and builder of premium cannabis brands including its sought after and popular brand Citizen Stash is pleased to report its first-quarter financial results for the three-month period ended February 28, 2021. Mr. Jarrett Malnarich, CEO of...

Read more

Apollo Endosurgery to Report First Quarter Financial Results on May 4, 2021

April 28, 2021 8:00 AM

AUSTIN, TX / ACCESSWIRE / April 28, 2021 / Apollo Endosurgery, Inc. ("Apollo") (NASDAQ:APEN), a global leader in next-generation minimally invasive medical devices for gastrointestinal and bariatric procedures, today announced that the Company is scheduled to release its financial results for the first quarter ended March 31, 2021 on Tuesday, May 4, 2021 after the market closes. In conjunction with the release, Apollo will host a...

Read more

Tetra Bio-Pharma Submits Request for Scientific Advice to Malta Medicines Authority

April 28, 2021 2:00 AM

Tetra plans for global commercialization of QIXLEEF OTTAWA, ON / ACCESSWIRE / April 28, 2021 / Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX:TBP)(OTCQB:TBPMF)(FRA:JAM1), a leader in cannabinoid-derived drug discovery and development announced today that it has submitted a request to the Malta Medicines Authority for a Scientific Opinion on its investigational new drug (IND) QIXLEEF for Tetra's clinical...

Read more